Trial Profile
An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Acronyms SUSTAIN-3
- Sponsors Janssen Research & Development; Janssen-Cilag
- 05 Sep 2023 According to a Janssen media release, sub-group analysis of this trial will be presented at the Psych Congress 2023.
- 09 Aug 2023 Interim results of subgroup analysis (n=32) assessing Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period published in the CNS Drugs
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.